Deltex Medical Group PLC Three new US platform programme accounts
September 08 2016 - 2:01AM
RNS Non-Regulatory
TIDMDEMG
Deltex Medical Group PLC
08 September 2016
8 September 2016
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
Three new US platform programme accounts
Deltex Medical Group plc (AIM: DEMG), the global leader in
oesophageal Doppler monitoring ("ODM"), is pleased to announce that
it has added three additional accounts to its platform programme in
the USA.
Two of the new platform accounts are in the Company's North-East
territory and the third in the Mid-West. They bring the total
number of platform accounts to 27, further illustrating the success
of the Company's focus on developing the USA as its key market.
-- The Company has designated one of three newly opened
paediatric hospital accounts as a platform account. It is one of
the largest and best regarded childrens' hospitals in the USA, thus
positioned to play a key role in developing and promoting ODM
applications in children. The Company's strategy in paediatric
accounts is to support incremental usage by individual clinicians
towards scaleable clinical protocols and is starting each account
from a low base.
-- The Company has opened two new hospitals within a six
hospital system planning to roll-out the successful enhanced
recovery programme from the largest hospital which has been a
platform account since 2014. One of the two new hospitals is
considerably larger than the other and has the potential to use
over 100 probes a month over time: its current plans would get it
to 50 to 60 probes a month by the end of 2017 and it has therefore
been designated a platform account.
-- The third account is a University level 1 trauma hospital.
The procurement agreement has neither minimum nor maximum
contractual quanities and the implementation model is predicated on
that deployed successfully at one of the Company's earliest and
largest platform accounts which uses 150 to 200 probes a month: the
new account has recruited one of the clinical leads from the
original account to lead the new implementation.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"Growth rates in the USA, our main focus market, continue to
climb and to outstrip other territories. These three new platform
accounts bring the total number to 27 and move us very close to our
key short term milestone of 30 platform accounts."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Barry Curtis, Company
Secretary
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Financial Public Relations
IFC Advisory 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's ODM is the only technology to
measure continuously blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM. Randomised,
controlled trials using Doppler have demonstrated that early fluid
management intervention will reduce post-operative complications,
reduce intensive care admissions, and reduce the length of hospital
stay.
Company goal
ODM is increasingly recognised as a standard of care for
patients undergoing major surgery and in critical care. The broader
clinical area of haemodynamic management of which ODM is a core
constituent is also now becoming widely accepted as an important
major new medical modality. Consequently, the Company's focus is on
maximising value from the opportunities presented as enhanced
haemodynamic management is adopted into routine clinical practice
around the world.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the
world and around 700,000 patients have been treated to date using
Deltex Medical's single patient disposable probes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUWWBUPQPGM
(END) Dow Jones Newswires
September 08, 2016 02:01 ET (06:01 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2023 to Apr 2024